Dr Reddy's shares rally 4% as Nuvama upgrades rating to buy

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Revlimids patent expiry in 2026. The brokerage set a target price of Rs 1,553, reflecting a 15% upside. Dr. Reddys is also expanding its portfolio with new drug launches and growth in core markets like India and China.